The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada

Παρόμοια τεκμήρια

• Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
  ανά: Cameron, Jodi, κ.ά.
  Έκδοση: (2014)
• Seminal fluid anaphylaxis
  ανά: Deria, Mariam, κ.ά.
  Έκδοση: (2011)
• Use of Omalizumab to treat a nine-year old, with steroid-dependent, allergic asthma, adrenal insufficiency and vertebral compression fractures due to steroid induced severe osteoporosis
  ανά: Ring, Alicia, κ.ά.
  Έκδοση: (2011)
• Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada
  ανά: Lee, Jason K, κ.ά.
  Έκδοση: (2020)
• Omalizumab treatment of moderate to severe asthma in the adolescent and pediatric population
  ανά: O’Quinn, John, κ.ά.
  Έκδοση: (2014)